An Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Japanese Subjects With Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Roniciclib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 31 Jul 2017 Planned End Date changed from 27 Apr 2018 to 26 Apr 2019.
- 08 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 24 Mar 2016 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017 as reported by ClinicalTrials.gov.